⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 17 in last 7 days 🍎 Food: 0 in last 7 days 🧸 Products: 113 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 5 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 17 in last 7 days 🍎 Food: 0 in last 7 days 🧸 Products: 113 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 5 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT June 3, 2026

Dipeptiven 200 mg/ml Konzentrat zur Herstellung einer Infusionslösung 200 mg/ml (Konzentrat zur Herstellung einer Infusionslösung)

📷 EU Safety Watch placeholder
Dipeptiven 200 mg/ml Konzentrat zur Herstellung einer Infusionslösung 200 mg/ml (Konzentrat zur Herstellung einer Infusionslösung)
📷 EU Safety Watch placeholder
Parallel export ban active for Dipeptiven 200 mg/ml concentrate for infusion solution.
⚠️
Shortage ongoing
N(2)-ALANYLGLUTAMIN is currently in short supply in AT.
📈 Timeline
6 days active so far
June 12, 2026 June 17, 2026

What is this? Dipeptiven is a liquid medicine given by drip. It helps people who cannot eat enough food.

What's happening? There is less of this medicine now because making it is taking longer.

Does this affect me? If you use this medicine in Austria, you may have trouble getting it.

What should I do? Ask your pharmacist or doctor before changing anything.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
N(2)-ALANYLGLUTAMIN
Agency-published detail

🚫 Parallel export ban active · ATC: B05XB02 · Reason: Verzögerung bei der Herstellung · Marketing authorisation holder: Fresenius Kabi Austria GmbH, Hafnerstraße 36, 8055 Graz, Österreich · Affected packs: 10 Stück Schachtel, Flasche [eingeschränkt verfügbar, since 2026-06-01, resupply 2026-09-15] · 10 Stück Schachtel, Flasche [verfügbar]

First published
June 3, 2026
Last refreshed by us
5 hours ago
Severity (as classified)
Medium
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Dipeptiven 200 mg/ml Konzentrat zur Herstellung einer Infusionslösung 200 mg/ml (Konzentrat zur Herstellung einer Infusionslösung). Parallel export ban active for Dipeptiven 200 mg/ml concentrate for infusion solution.
▸ When was this alert issued?
This alert was issued on June 3, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Medium risk. A medium risk means harm is possible under certain conditions. Read the notice and act on the recommended steps.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.